Home › NDC Lookup › RxCUI directory › RxCUI 197602

Diflunisal 250 MG Oral Tablet — RxCUI 197602

RxNorm drug concept · Semantic clinical drug
RxCUI 197602 Semantic clinical drug · SCD ● Current RxNorm concept 3 FDA products 5 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI197602
Official nameDiflunisal 250 MG Oral Tablet
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
FDA products mapped3
Package NDCs mapped5
Reported Medicaid activity (SDUD)18,856 prescriptions · 11 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Diflunisal: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Diflunisal is an anti-inflammatory pain reliever — an NSAID — used to treat mild to moderate pain and to help manage the symptoms of osteoarthritis and rheumatoid arthritis. It can...
  • Swallow the tablets whole — don't crush or chew them. For pain, you'll usually take a higher first dose to get things working, then a lower dose every 8 to 12 hours after that. For...
  • The most common ones are stomach-related — nausea, stomach pain, diarrhea, and sometimes constipation. You might also notice headache, dizziness, or ringing in your ears. Most of t...
  • What side effects should I watch out for?
📖 Read our full Diflunisal guide →

🕸️ Concept Web — How Diflunisal 250 MG Oral Tablet Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Diflunisal 250 MG Oral Tablet RxCUI 197602

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Diflunisal 3393
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Dolobid 202486
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Diflunisal Oral Tablet 371828
    • Diflunisal Oral Product 1151511
    • Diflunisal Pill 1151512
    • Diflunisal Oral Tablet [Dolobid] 369174
    • Dolobid Oral Product 1174563
    • Dolobid Pill 1174564
    • Oral Tablet 317541
    • Oral Product 1151131
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Diflunisal 250 MG SCDC · 317354
  • Diflunisal Oral Tablet SCDF · 371828
  • Diflunisal Oral Product SCDG · 1151511
  • Diflunisal Pill SCDG · 1151512

Brand-Name Concepts

  • Diflunisal 250 MG Oral Tablet [Dolobid] SBD · 105823
  • Diflunisal 250 MG [Dolobid] SBDC · 564179
  • Diflunisal Oral Tablet [Dolobid] SBDF · 369174
  • Dolobid Oral Product SBDG · 1174563
  • Dolobid Pill SBDG · 1174564
  • Dolobid BN · 202486

📦 FDA Products & Package NDCs

3 products · 5 package NDCs
5 package NDCs map to RxCUI 197602 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
14539-0673-01 100 TABLET, FILM COATED in 1 BOTTLE (14539-673-01) diflunisal Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc. 2019-01-09
14539-0673-05 500 TABLET, FILM COATED in 1 BOTTLE (14539-673-05) diflunisal Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc. 2019-01-09
14539-0673-06 60 TABLET, FILM COATED in 1 BOTTLE (14539-673-06) diflunisal Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc. 2019-01-09
74157-0009-60 60 TABLET, FILM COATED in 1 BOTTLE (74157-009-60) Dolobid INA Pharmaceutics Inc 2024-08-19
74157-0101-60 60 TABLET, FILM COATED in 1 BOTTLE (74157-101-60) Dolobid INA Pharmaceutics Inc 2024-08-19
Observed labelers: Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc. (3) · INA Pharmaceutics Inc (2) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.